Enovis CORP
boothcheck covers Enovis CORP (ENOV) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Two businesses of roughly equal size sit inside Enovis: a bracing and recovery franchise the 10-K describes as operating where ⟦"The markets in which our Prevention & Recovery segment competes are highly competitive and fragmented."⟧, and a surgical implant business assembled largely by acquisition. • The accounting has already conceded what those acquisitions cost, with goodwill write-offs of $1,049.8 million recorded during 2025 on top of $645.0 million the year before. • The nearer question
Is ENOV overvalued? See what's priced in →
244 institutional managers reported holding ENOV in 13F filings for the quarter ended 2026-03-31. 43 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 9.0M shares were sold short as of the 2026-06-15 count, about 16% of shares outstanding (8.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ENOV has cut its share count 62.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ENOV over the trailing three years: 2025: 5 buys totaling $739k; 2026: 12 buys totaling $238k. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ENOV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -5.8% | -15.7% |
| 2023-11-08 | +4.0% | +21.2% |
| 2024-02-23 | +4.3% | -12.1% |
| 2024-05-03 | -7.5% | -12.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ENOV's latest 8-K filings: 2026-09-01 (items 7.01, 9.01); 2026-08-06 (items 2.02, 9.01); 2026-05-19 (items 5.02, 5.07, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-02-26 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.